Endocyte Reports Second Quarter Financial Results and Provides Clinical Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. MIRM
2. SPY
3. META
4. MSFT
5. PLTR
6. JNJ
7. QQQ
8. LDOS
9. HUM
10. CSCO

Go back to Endocyte Reports Second Quarter Financial Results and Provides Clinical Update

Chardan Capital Affirms Endocyte (ECYT) at Buy Following Q2 Results, Operational Update

July 30, 2014 2:49 PM EDT

Chardan Capital affirms Endocyte (Nasdaq: ECYT) at Buy with a price target of $15 following Q2 results and updated information of EC1456.

Analyst Ling Wang commented, ECYT reported 2Q14 EPS of $0.54, vs. consensus... More